Ovarian cancer in the older patient: where are we now? What to do next? by Frédérique Rousseau, Florence Ranchon, Christophe Bardin, Naoual Bakrin, Vincent Lavoué, Leila Bengrine-Lefevre, Claire Falandry

Get full text

Association of 5-FU Therapeutic Drug Monitoring to DPD Phenotype Assessment May Reduce 5-FU Under-Exposure by Marine Dolat, Pauline Macaire, Françoise Goirand, Julie Vincent, Audrey Hennequin, Rémi Palmier, Leïla Bengrine-Lefevre, François Ghiringhelli, Bernard Royer, Antonin Schmitt

Get full text

Impact of therapeutic strategy on disease‐free and overall survival of early‐stage cervical cancer: Surgery alone versus preoperative radiation by Katia Mahiou, Laura Vincent, Karine Peignaux‐Casasnovas, Hélène Costaz, Marie‐Martine Padeano, Alix Amet, Sandrine Dabakuyo, Ariane Mamguem Kamga, Leila Bengrine‐Lefevre, Charles Coutant

Get full text

Improving olaparib exposure to optimize adverse effects management by Marylise Sterlé, Alicja Puszkiel, Chloé Burlot, Eva Pereira, Audrey Bellesoeur, Sixtine De Percin, Guillaume Beinse, Jean-David Fumet, Laure Favier, Julie Niogret, Benoit Blanchet, Bernard Royer, Leïla Bengrine-Lefevre, Antonin Schmitt

Get full text

Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial by Isabelle L. Ray-Coquard, Aude-Marie Savoye, Camille Schiffler, Marie-Ange Mouret-Reynier, Olfa Derbel, Elsa Kalbacher, Marianne LeHeurteur, Alejandra Martinez, Corina Cornila, Mathilde Martinez, Leila Bengrine Lefevre, Frank Priou, Nicolas Cloarec, Laurence Venat, Frédéric Selle, Dominique Berton, Olivier Collard, Elodie Coquan, Olivia Le Saux, Isabelle Treilleux, Sophie Gouerant, Antoine Angelergues, Florence Joly, Olivier Tredan

Get full text